Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

14.98 +0.26 (+1.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,829,894
Open 14.84
Bid (Size) 14.80 (5)
Ask (Size) 14.95 (35)
Prev. Close 14.72
Today's Range 14.35 - 15.48
52wk Range 12.24 - 28.05
Shares Outstanding 161,429,360
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
67 Biggest Movers From Yesterday
Gainers Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital. 
Via Benzinga
Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis
HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&# 
Via Benzinga

Performance

YTD
-38.58%
-38.58%
1 Month
-7.70%
-7.70%
3 Month
-39.23%
-39.23%
6 Month
-38.40%
-38.40%
1 Year
-42.76%
-42.76%

More News

Read More
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 33% Today?
Via InvestorPlace
Why Acadia Pharma Shares Are Plunging Today
Via Benzinga
Why ACADIA Pharmaceuticals Shares Are Trading Higher Today?
Via Benzinga
Nasdaq Rises 2.5%; ACADIA Pharmaceuticals Shares Plummet
Via Benzinga
Dow Jumps 550 Points; Convey Health Solutions Shares Spike Higher
Via Benzinga
45 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
U.S. Markets Open Higher; Lennar Earnings Top Views
Via Benzinga
Acadia Pharmaceuticals Crashes After FDA Panel Votes Down Its Alzheimer's Psychosis Drug
Via Investor's Business Daily
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Via Benzinga
Acadia Pharmaceuticals Announces Outcome of FDA Advisory Committee for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis
From Acadia Pharmaceuticals Inc.
Via Business Wire
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
Via Benzinga
Acadia Pharmaceuticals Stock Trading Halted Today
From Acadia Pharmaceuticals Inc.
Via Business Wire
HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate
Via Benzinga
71 Biggest Movers From Yesterday
Via Benzinga
Why Acadia Pharma Surged Despite A Negative FDA Take On Its Lead Drug
Via Investor's Business Daily
55 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
5 Biotech Stocks To Watch During The Week Of June 13
Via Benzinga
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Via Benzinga
This Biotech Looks Good With Increased M&A activity
Via Talk Markets
ACADIA Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
ACADIA Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.